Figure 2.
Exhausted CD8+T cells can be defined by lack of DNAM-1 expression in mice with relapsed myeloma after SCT. MM-bearing or naive (MM-free; green) recipients were transplanted as previously described with BM+T grafts from B6 donors. MM-bearing mice were categorized as MM relapsed (purple) or MM controlled (orange) at 6 or 8 weeks after SCT. Mice were sacrificed, BM and spleen were harvested, and CD8+ T cells were analyzed using flow cytometry. FACS plots and histograms are representative. (A-C) Phenotyping performed on CD8+ T cells from BM of MM-relapsed mice. (A) CD44 and CD62L populations in PD-1− or TIGIT+ or PD-1+ or LAG-3+ or TIM-3+ subsets. Frequency of TEFF/EM (CD44+CD62L−) cells within each positive subset was compared with PD-1− cells (n = 5-11 combined from 2 to 4 experiments). (B) Frequency of TIGIT and PD-1 coexpression (n = 13-18 combined from 5 experiments). (C) Frequency of TIM-3 and LAG-3 coexpression on PD-1+ CD8+ T cells from BM of MM-relapsed mice (n = 11 combined from 4 experiments). (D) Frequency of CD101+CD38+ and CD101−CD38− CD8+ T cells (n = 8-11 from 2 experiments) and (E) t-distributed stochastic neighbor embedding (tSNE) analysis and frequency of exhausted and responsive CD8+ T-cell phenotypes in BM of MM-relapsed, MM-controlled, and MM-free mice (n = 4-8; representative of 2 independent experiments). (F) Frequency of PD-1 and TIGIT expression on DNAM-1+ (teal) and DNAM-1− (magenta) subsets (n = 16 combined from 6 experiments). (G) Frequency of EomeshiT-betdim/− CD8+ T cells in DNAM-1+ and DNAM-1− subsets from MM-relapsed mice (n = 10 combined from 2 experiments). (H) Frequency of Eomes expression within DNAM-1+ and DNAM-1− subsets from BM of MM-relapsed mice (n = 10 combined from 2 experiments). (I) Recipients were transplanted with FoxP3-RFP × IL-10-GFP reporter donors. Frequency of IL-10 producing CD8+ T-cells within DNAM-1+ and DNAM-1− subsets in BM of MM-relapsed mice (n = 8 combined from 3 experiments). Data represent mean ± SEM. Mann-Whitney U test. **P < .01, ***P < .001.

Exhausted CD8+T cells can be defined by lack of DNAM-1 expression in mice with relapsed myeloma after SCT. MM-bearing or naive (MM-free; green) recipients were transplanted as previously described with BM+T grafts from B6 donors. MM-bearing mice were categorized as MM relapsed (purple) or MM controlled (orange) at 6 or 8 weeks after SCT. Mice were sacrificed, BM and spleen were harvested, and CD8+ T cells were analyzed using flow cytometry. FACS plots and histograms are representative. (A-C) Phenotyping performed on CD8+ T cells from BM of MM-relapsed mice. (A) CD44 and CD62L populations in PD-1 or TIGIT+ or PD-1+ or LAG-3+ or TIM-3+ subsets. Frequency of TEFF/EM (CD44+CD62L) cells within each positive subset was compared with PD-1 cells (n = 5-11 combined from 2 to 4 experiments). (B) Frequency of TIGIT and PD-1 coexpression (n = 13-18 combined from 5 experiments). (C) Frequency of TIM-3 and LAG-3 coexpression on PD-1+ CD8+ T cells from BM of MM-relapsed mice (n = 11 combined from 4 experiments). (D) Frequency of CD101+CD38+ and CD101CD38 CD8+ T cells (n = 8-11 from 2 experiments) and (E) t-distributed stochastic neighbor embedding (tSNE) analysis and frequency of exhausted and responsive CD8+ T-cell phenotypes in BM of MM-relapsed, MM-controlled, and MM-free mice (n = 4-8; representative of 2 independent experiments). (F) Frequency of PD-1 and TIGIT expression on DNAM-1+ (teal) and DNAM-1 (magenta) subsets (n = 16 combined from 6 experiments). (G) Frequency of EomeshiT-betdim/− CD8+ T cells in DNAM-1+ and DNAM-1 subsets from MM-relapsed mice (n = 10 combined from 2 experiments). (H) Frequency of Eomes expression within DNAM-1+ and DNAM-1 subsets from BM of MM-relapsed mice (n = 10 combined from 2 experiments). (I) Recipients were transplanted with FoxP3-RFP × IL-10-GFP reporter donors. Frequency of IL-10 producing CD8+ T-cells within DNAM-1+ and DNAM-1 subsets in BM of MM-relapsed mice (n = 8 combined from 3 experiments). Data represent mean ± SEM. Mann-Whitney U test. **P < .01, ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal